Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial [Thoracic Oncology]

Conclusion
Adjuvant erlotinib did not prolong DFS in patients with EGFR-expressing NSCLC or in the EGFRm-positive subgroup. Further evaluation of erlotinib is warranted in the EGFRm-positive subgroup.

Source: Journal of Clinical Oncology - November 25, 2015 Category: Cancer & Oncology Authors: Kelly, Altorki, Eberhardt, O'Brien, Spigel, Crino, Tsai, Kim, Cho, Hoffman, Orlov, Serwatowski, Wang, Foley, Horan, Shepherd Tags: Surgery, Chemotherapy Thoracic Oncology Source Type: research